ROARABLE
FREE $100K
Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / KMTS / options
LMAT (67) XRAY (32) INSP (65) NVCR (20) ⌘ Pro Terminal β†’

Kestra Medical Technologies Ltd. (KMTS) Options Positioning, Max Pain & Unusual Sweeps

$29.81 +0.40% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $29.77

Kestra Medical Technologies Ltd. (KMTS) carries a Roarable Rating of D (Sell) with 50/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D β€’ SELL / AVOID Cap $1.77B
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on KMTS Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is KMTS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Kestra Medical Technologies Ltd. (NASDAQ: KMTS) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 50/100 at a spot price of $29.81 (+0.40% 1D, market cap $1.77B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, KMTS ranks #261 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does KMTS compare to LMAT and XRAY in the Health Care sector?
β–Ό

Within the Health Care sector (Medical/Dental Instruments), KMTS carries a Roarable D (50/100 RQD), trailing P/E of N/A, gross margin of 51.4%, and ROIC of -35.0%. By comparison, LMAT (LeMaitre Vascular Inc.) holds a C+ grade (67/100 RQD, P/E 33.8x, ROIC 14.7%, cap $1.85B) and XRAY (DENTSPLY SIRONA Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -11.0%, cap $1.90B). Among the 5-stock peer group, INSP leads on earnings multiple (14.2x) while LMAT leads on capital efficiency (14.7% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for KMTS?
β–Ό

Per KMTS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-04-30, CIK 0001877184), Kestra Medical Technologies Ltd. generated $95.1M in revenue (+59.0% YoY), -$131.6M in net income, and -$116.6M in free cash flow against $379.3M in total assets and $42.3M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $29.77 (-0.12%)🧬 Dilution Drag (+2.48% YoY Shares)βš™οΈ Cash Engine: 8/20 (D-) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record: Scores of 50/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.4% avg 90D alpha vs SPY β€’ 49.3% hit rate β€” wait for RQD β‰₯ 70 breakout).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERSELL / AVOID β€’ D
025507510050
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D Β· Rk D+
Cash (8)Whales (16)SEC (14)Macro (9)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-3.6% Base Target
$34 Bull$29 Base$22 Bear
πŸ“¬ FREE KMTS RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for KMTS)Realized 20D OHLCV Swing Band: Β±11.9%
Deterministic 5-Pillar Attribution (50/100 Composite)
πŸ” WHY KMTS SCORES 50/100 (D) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Whale & Options Positioning+16/20 pts (32% of score)

20D Institutional Volume Accumulation (Β±11.9% realized swing band)

β–² #2 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (28% of score)

Altman Z-Score 9.65 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 5/9

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
42
Grade D$26.97+4.9% Next Q
Q2 (-2Q)
45
Grade D$28.28+6% Next Q
Q3 (-1Q)
47
Grade D$29.99-0.6% Next Q
Current
50
Grade D$29.81-1.4% Hist 90D Ξ±
Trajectory: D (42) β†’ D (50)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a KMTS Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While KMTS currently carries a cautious 50/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Big institutional funds and options desks are actively positioning on the bullish side.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($26.82) and Max Pain ($31.30) forces dealer call-delta covering toward $33.91.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $KMTSβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œKMTS Beats Next Quarter EPS Consensus (Jan 28, 2027) & Holds Above 200D SMA”
YES 50%NO 50%Trade / Inspect Odds β†’
CALL VS. PUT WHALE SHARE
β€” (No Active Options Snapshot)
Put/Call Ratio: β€” (No Active Options Snapshot)
MAX-PAIN EXPIRATION MAGNET
β€” (No Active Options Snapshot)
No active options chain max-pain snapshot on file
HISTORICAL 20D VOLATILITY SWING
Β±11.9%
Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (KMTS)

β€” (No Active Options Snapshot) β€” No unusual CBOE strike concentration anomalies recorded in the current database snapshot for KMTS.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

πŸ† Enter Free $100K Paper Arena β†’
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring KMTS)

  • βœ“Walkthrough of KMTS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
KMTS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +45.06%β–² ASCENDING CHANNEL
2026-11-03O $30.61H $30.61L $29.69C $29.81VOL 324.9K
RES: $31.15SUP: $23.37SMA50: $26.82SMA200: $23.89
$31.98$28.16$24.34$20.52$16.69RES $31.15SUP $23.37$29.812026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

KMTS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ KMTS Butterfly Map β†’ + Track KMTS β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +59.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on KMTS today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for KMTS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for KMTS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (KMTS)

Health Care Rank #261 of 1016 βš”οΈ LMAT vs KMTS Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (KMTS vs. LMAT, XRAY, INSP, NVCR)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Kestra Medical Technologies Ltd. (KMTS) ranks #261 by composite RQD confidence (50/100, grade D) and #275 by equity capitalization ($1.77B). Within this direct 5-issuer industry benchmark cohort, INSP leads on earnings valuation at 14.2x trailing P/E, while LMAT leads on capital efficiency and profitability with 14.7% ROIC and 71.5% gross margin. LMAT currently holds the highest overall quantitative score in the immediate peer group at 67/100 (C+) compared with KMTS at 50/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
KMTS ACTIVE
Kestra Medical Technologies Ltd.
D 50/100 β€” 51.4% -35.0% +0.40% $1.77B Benchmark Subject
LMAT
LeMaitre Vascular Inc.
C+ 67/100 33.8x 71.5% 14.7% +0.40% $1.85B /lmat-vs-kmts β†’
XRAY
DENTSPLY SIRONA Inc.
E 32/100 β€” 50.0% -11.0% +3.88% $1.90B /xray-vs-kmts β†’
INSP
Inspire Medical Systems Inc.
C 65/100 14.2x 85.4% 6.0% -1.31% $1.97B /insp-vs-kmts β†’
NVCR
NovoCure Limited
E 20/100 β€” 74.5% -27.5% +0.46% $1.54B /nvcr-vs-kmts β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2026-04-30 β€’ CIK 0001877184

In its most recent audited fiscal period (FY2025, filed 2026-04-30), Kestra Medical Technologies Ltd. (KMTS) reported GAAP revenue of $95.1M (+59.0% vs. FY2024 revenue of $59.8M , and +242.0% cumulative change since FY2023) , GAAP net income of -$131.6M, operating cash flow of -$81.7M, and free cash flow of -$116.6M (-16.0% YoY). On the balance sheet, KMTS closed FY2025 with $379.3M in total assets against $42.3M in total debt (Altman Z-Score: 9.65, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2026-04-30 $95.1M -$131.6M -$81.7M -$116.6M $379.3M $42.3M
FY2024 (FY) 2025-04-30 $59.8M -$113.8M -$77.6M -$100.5M β€” β€”
FY2023 (FY) 2024-04-30 $27.8M -$94.1M -$72.2M -$72.2M β€” β€”

3. KMTS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is KMTS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Kestra Medical Technologies Ltd. (NASDAQ: KMTS) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 50/100 at a spot price of $29.81 (+0.40% 1D, market cap $1.77B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, KMTS ranks #261 in composite RQD confidence.

How does KMTS compare to LMAT and XRAY in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), KMTS carries a Roarable D (50/100 RQD), trailing P/E of N/A, gross margin of 51.4%, and ROIC of -35.0%. By comparison, LMAT (LeMaitre Vascular Inc.) holds a C+ grade (67/100 RQD, P/E 33.8x, ROIC 14.7%, cap $1.85B) and XRAY (DENTSPLY SIRONA Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -11.0%, cap $1.90B). Among the 5-stock peer group, INSP leads on earnings multiple (14.2x) while LMAT leads on capital efficiency (14.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for KMTS?

Per KMTS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-04-30, CIK 0001877184), Kestra Medical Technologies Ltd. generated $95.1M in revenue (+59.0% YoY), -$131.6M in net income, and -$116.6M in free cash flow against $379.3M in total assets and $42.3M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is KMTS trading relative to its 50-day, 200-day, and 52-week technical levels?

KMTS last traded at $29.81 (+0.40% on volume of 412,052 shares), positioning the stock +11.15% above its 50-day simple moving average ($26.82) and +24.78% above its 200-day simple moving average ($23.89). Across its 52-week range of $17.34 to $31.06, KMTS sits at the 90.9% percentile with a 14-day RSI of 56.2 (BULLISH MOMENTUM) and an implied next-earnings move of Β±11.9% ($26.26 to $33.36).

Direct Sub-Reports: KMTS RQD Cockpit KMTS 12M Forecast KMTS Earnings & Move KMTS Dividends & DRIP KMTS Insiders & 13F KMTS Whale Options KMTS Profit Sankey KMTS News & Why
ROARABLE RATING BRIEF β€’ RQD 50/100 (D) βœ“ SEC XBRL & RQD VERIFIED

KMTS β€” Kestra Medical Technologies Ltd.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-04-30

1. Roarable Rating Brief: What This Means to a Prospective Investor

Kestra Medical Technologies Ltd. (KMTS) earns a live Roarable RQD composite score of 50/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $29.81 (+0.40% 1D, market capitalization $1.77B).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 51.4%, operating margin of -60.0%, and free cash flow yield of -6.40%.
  • Whale 13F & Options Flow (16/20) + Insider Conviction (14/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (3/20): Incorporates a 1.00x equity beta, Altman Z-Score of 9.65, Piotroski F-Score of 5/9, and Debt/Equity of 0.15x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Kestra Medical Technologies Ltd. (KMTS) is a NASDAQ-listed issuer in the Health Care sector, operating in the Medical/Dental Instruments industry. It carries a market capitalization of $1.8B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2026-04-30), Kestra Medical Technologies Ltd. (KMTS) reported $95.1M in annual revenue (up from $59.8M in FY2024, +59.0% YoY) and -$131.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($27.8M revenue, -$94.1M net income) through FY2025, KMTS scaled operating cash flow to -$81.7M and free cash flow to -$116.6M, backed by $379.3M in total assets against $42.3M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (D β€’ RQD 50/100): Big institutional funds and options desks are actively positioning on the bullish side. Free cash flow yield of -6.40% and institutional whale pillar of 16/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 16/20, sustained execution supports upside toward the upper end of the $17.34 – $31.06 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Medical/Dental Instruments (Health Care), KMTS carries a macro regime beta of 1.00 and gross margin of 51.4%.

  • Key Question #1: Can KMTS sustain or expand its -60.0% operating margin and -35.0% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $95.1M and free cash flow of -$116.6M, how will capital allocation balance growth reinvestment against $42.3M in total debt?
  • Key Question #3: How sensitive is KMTS's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

KMTS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Kestra Medical Technologies Ltd. (KMTS) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to KMTS Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

KMTS Bull vs. Bear Conversation Board β€” What's Your Call at $29.81?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON KMTS 🐻 33% BEARISH CONVICTION
1. Pick Your Side on KMTS:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER β€’ Systematic Momentum Desk πŸ‚ BULLISH 🎯 Target: $39.19 (+32.0%)
πŸ“Œ Pinned Debate

Institutional accumulation and options positioning score 16/20 and the balance sheet is strong on forensic measures, with an Altman Z o

Long KMTS at $29.69 targeting $39.19. Institutional accumulation and options positioning score 16/20 and the balance sheet is strong on forensic measures, with an Altman Z of 9.65 and cash of $291.3M against debt of $42.3M.. Institutional whale score is 16/20 and the risk/reward vs. the $17.34 52-week low is skewed heavily in favor of bulls.

RetailWhale_TX πŸ‚ BULL

Both sides have a point here β€” KMTS's 14/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

FO ForensicBear RQD DEBATE OPENER β€’ 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $25.53 (-14.0%)
Spot @ $29.69

ROIC of -35%, FCF yield of -6.4%, and a -$116.6M FY 2025 free cash flow outflow, paired with a 3/20 insider conviction score, point to

I respect the product at Kestra Medical Technologies Ltd., but the stock at $29.69 is a different story. ROIC of -35%, FCF yield of -6.4%, and a -$116.6M FY 2025 free cash flow outflow, paired with a 3/20 insider conviction score, point to a business still burning cash.. FCF yield is -6.4% and RQD sits at 50/100 (D) β€” why pay up here when you can wait for next quarter's numbers?

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%